1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
SEC FILE NUMBER
0-9065
NOTIFICATION OF LATE FILING
CUSIP NUMBER
38114510 1
(Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K
[x] Form 10-Q [ ] Form N-SAR
For Period Ended: November 30, 1997
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
Golden Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
Full Name of Registrant
- --------------------------------------------------------------------------------
Former Name if Applicable
710 14th Street
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Golden, Colorado 80401
- --------------------------------------------------------------------------------
City, State and Zip Code
2
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check appropriate box)
[x] (a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable
effort or expense;
[x] (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or
portion thereof, will be filed on or before the fifteenth
calendar day following the prescribed due date; or the
subject quarterly report of transition report on Form 10-Q,
or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period.
On April 7, 1997, the Registrant completed the sale of its assets related to
its business of manufacturing and distributing Iodine-123 capsules for a total
purchase price of $6,700,000. In addition, the Company moved its accounting
department from Colorado to California and replaced its entire accounting
department. As a result the Registrant is unable to timely complete the
information required for the presentation of its Quarterly Report on Form
10-QSB for the quarter ended November 30, 1997.
3
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Gary P. Pryor (303) 279-9375
------------------------------- --------------------- ----------------
(Name) (Area Code) (Telephone
Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter
period that the registrant was required to file such report(s) been
filed? If answer is no, identify report(s).
[x] Yes [ ] No
- --------------------------------------------------------------------------------
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof?
[x] Yes [ ] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
================================================================================
Golden Pharmaceuticals, Inc.
--------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date January 15, 1998 By /s/ Gary P. Pryor
------------------------- ---------------------------------------
Gary P. Pryor, Vice President,
Finance
4
PART IV - OTHER INFORMATION
3. The Registrant believes that due to the sale of the assets in April
1997 and a decrease in sales in Pharma Labs and Quality Care
Pharmaceuticals, Inc., there will be a significant change in the
results of operations from the same period during the last fiscal
year, however, a reasonable estimate of the results cannot be made at
this time.